AKUMS
Akums Drugs and Pharmaceuticals Limited (AKUMS) Stock Analysis
Akums Drugs and Pharmaceuticals Limited is an Indian contract manufacturer of pharmaceutical formulations. It produces medicines for domestic and global clients across dosage forms and therapies. The company is among the larger CDMO players listed in India. It serves generic and innovator customers from multiple plants.
Healthcare › Drug Manufacturers - Specialty & Generic
₹731.50
-2.71% 1W | +62.40% 52W
Market Cap
11.2k CR
P/E Ratio
38.4
52W High
₹838.8
52W Low
₹409.3
Div. Yield
0.13%
Beta
0.6
50 DMA
₹772.9
200 DMA
₹595.5
Profit Margin
6.5%
Inst. Own.
12.6%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 970 | 1,181 | 1,083 | 944 | 1,019 | 1,033 | 1,010 | 1,056 | 1,024 | 1,018 | 1,160 | 1,158 | 1,167 |
| Expenses | 1,095 | 1,029 | 989 | 941 | 891 | 912 | 889 | 962 | 895 | 923 | 1,013 | 1,006 | 992 |
| Operating Profit | -125 | 152 | 93 | 3 | 128 | 121 | 121 | 94 | 129 | 94 | 147 | 152 | 175 |
| OPM % | -13% | 13% | 9% | 0.3% | 13% | 12% | 12% | 9% | 13% | 9% | 13% | 13% | 15% |
| Other Income | 8 | -21 | 10 | 10 | 7 | 17 | 19 | 26 | 27 | 32 | 16 | 34 | 30 |
| Interest | 12 | 14 | 12 | 12 | 13 | 12 | 5 | 5 | 23 | 23 | 24 | 24 | 25 |
| Depreciation | 30 | 30 | 32 | 34 | 34 | 35 | 45 | 40 | 37 | 38 | 40 | 40 | 41 |
| Profit before tax | -159 | 87 | 59 | -33 | 87 | 92 | 91 | 75 | 96 | 66 | 100 | 121 | 139 |
| Tax % | 18% | 62% | -229% | 20% | 30% | 27% | 27% | -99% | 32% | 35% | 32% | 33% | 27% |
| Net Profit | -187 | 33 | 195 | -39 | 61 | 67 | 66 | 150 | 65 | 43 | 68 | 81 | 101 |
| EPS in Rs | -13.16 | 2.22 | 13.54 | -2.89 | 4.08 | 4.14 | 4.14 | 9.38 | 4.03 | 2.59 | 4.21 | 5.38 | 6.35 |
| Metric | Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,464 | 1,651 | 2,414 | 2,723 | 3,672 | 3,655 | 4,178 | 4,118 | 4,359 | 4,502 |
| Expenses | 1,340 | 1,507 | 2,240 | 2,485 | 3,761 | 3,361 | 4,055 | 3,654 | 3,837 | 3,934 |
| Operating Profit | 124 | 144 | 174 | 238 | -89 | 294 | 123 | 465 | 522 | 568 |
| OPM % | 8% | 9% | 7% | 9% | -2.4% | 8% | 3.0% | 11% | 12% | 13% |
| Other Income | 6 | 6 | 26 | 11 | 7 | 15 | 8 | 69 | 108 | 112 |
| Interest | 23 | 22 | 20 | 7 | 17 | 46 | 51 | 35 | 94 | 96 |
| Depreciation | 31 | 38 | 67 | 70 | 95 | 113 | 126 | 153 | 155 | 159 |
| Profit before tax | 77 | 89 | 114 | 172 | -193 | 150 | -45 | 345 | 382 | 426 |
| Tax % | 51% | 50% | 62% | 28% | 30% | 35% | -102% | 0% | 33% | |
| Net Profit | 43 | 61 | 44 | 123 | -251 | 98 | 1 | 344 | 256 | 293 |
| EPS in Rs | 366.55 | 523.23 | 335.61 | 943.49 | -35.30 | 6.63 | -0.28 | 21.49 | 16.21 | 18.53 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 18% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 6.0% | 10.0% | 10.0% |
| Profit CAGR | 29.0% | 16.0% | 16.0% |
Shareholding Pattern
Promoters75.26%
FIIs4.24%
DIIs8.85%
Public8.92%
Promoters75.26%
FIIs2.27%
DIIs9.28%
Public10.46%
Promoters75.26%
FIIs1.14%
DIIs14.41%
Public6.45%
Promoters75.26%
FIIs1.38%
DIIs14.36%
Public6.29%
Promoters75.26%
FIIs1.91%
DIIs13.44%
Public6.67%
Promoters75.26%
FIIs5.77%
DIIs7.39%
Public8.84%
Promoters75.26%
FIIs1.38%
DIIs14.36%
Public6.29%
Promoters75.26%
FIIs1.91%
DIIs13.44%
Public6.67%
AKUMS
Holdings Analysis
Key strengths & risk signals
76
Overall
79
Fundamental
74
Technical
Risks (3)
LOW MARGIN! 6.5% profit margin - thin profits.
RECOVERY MODE! Current price (731.5) above 200-day but below 50-day.
WEAK MOMENTUM! Limited price growth - -2.7% (1 week), -5.2% (1 month), 10.0% (3 months).
Strengths (4)
UNDERVALUED! PEG of 0.98 indicates stock is cheap relative to growth.
BULLISH TREND! 50-day average (772.9) is above 200-day average (595.5) - positive signal.
EXCELLENT YEAR! Stock gained 62.4% in the last year.
LOW VOLATILITY! Beta of 0.60 - stable stock, less market risk.
Fundamental & Technical Analysis
76Overall
79Fundamental
74Technical
Fundamental Breakdown
Growth Quality
23/30
Revenue CAGR: 7.0% (MODERATE, 8/15). Profit CAGR: 39.1% (EXCELLENT, 15/15).
Profit Margin
3/10
LOW MARGIN! 6.5% profit margin - thin profits.
PEG Valuation
10/10
UNDERVALUED! PEG of 0.98 indicates stock is cheap relative to growth.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.13% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
20/20
VERY LESS PUBLIC HOLDING! 7.14% public ownership - strong promoter/institutional control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (772.9) is above 200-day average (595.5) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (731.5) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
10/10
EXCELLENT YEAR! Stock gained 62.4% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 297,585 vs down days: 222,219. Ratio: 1.34x
RSI
4/5
APPROACHING OVERSOLD! RSI at 38.2 - watch for reversal.
52W Range
4/5
UPPER HALF! Trading at 75.0% of 52W range - positive territory.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -2.7% (1 week), -5.2% (1 month), 10.0% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.60 - stable stock, less market risk.
AKUMS
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-13 | Concall PDF | |
| Q4FY262026-05-21 | Concall PDF | |
| Q3FY262026-02-19 | Concall PDF | |
| Q2FY262025-11-17 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AKUMS | ₹731.50 | 38.4 | 6.5% | 7.0% | 39.1% | +62.4% | 76 | BREAKDOWN | +57.5% | +18.2% | +13.9% | +0.8% |
| SUDEEPPHRM | ₹1,000.70 | 61.4 | 27.0% | 14.4% | 40.5% | +36.3% | 73 | BREAKDOWN | +31.8% | -17.0% | +26.7% | -13.2% |
| VIYASH | ₹226.00 | 55.3 | 5.9% | 33.3% | – | +15.1% | 60 | BOUNCE FROM SUPPORT | +107.2% | +26.5% | +19.6% | +2.9% |
| STAR | ₹1,045.20 | 15.7 | 12.3% | 8.7% | – | +34.5% | 64 | BREAKDOWN | +57.5% | +23.6% | +13.0% | -4.4% |
| SEQUENT | ₹201.20 | 123.4 | 2.5% | 3.1% | -18.9% | +26.2% | 55 | CONSOLIDATION | -13.9% | +161.2% | +10.9% | +102.5% |
| SUVEN | ₹303.60 | – | – | -19.3% | – | +49.1% | 55 | BREAKDOWN | +147.8% | +179.8% | +89.5% | +140.0% |
| PGHL | ₹5,200.00 | 24.2 | 24.9% | 8.2% | 19.3% | -16.2% | 71 | CONSOLIDATING DOWN | +45.3% | +1.7% | +7.4% | -1.8% |
| NATCOPHARM | ₹785.00 | 12.4 | 32.8% | 14.5% | 25.6% | -4.8% | 66 | APPROACHING SUPPORT | -57.0% | -22.9% | -44.7% | -0.5% |
Data from TradeAlone · Updated daily
AKUMS News
Akums Drugs and Pharmaceuticals Limited (akums) Q2 FY27: Revenue Up 32%, Ebitda and PAT Surge2026-11-02Akums Drugs and Pharmaceuticals Limited (AKUMS) breaks out, gains 5% intraday2026-08-10Akums Drugs and Pharmaceuticals Limited (akums) Q1 FY27: Revenue Up 13.9% Yoy2026-08-08Akums Drugs and Pharmaceuticals Limited (NSE: AKUMS) gains 5% intraday2026-08-07Akums Drugs and Pharmaceuticals Limited (NSE: AKUMS) breaks out, moves up 5% intraday2026-07-10Akums Drugs and Pharmaceuticals Limited (akums) Q4 FY26: Revenue Up 9.7%, Ebitda Surges 61.6%2026-05-14
